Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medivation Battles UCLA Over Rights To Prostate Cancer Compound

Executive Summary

UCLA researchers secretly developed a compound almost identical to Medivation’s MDV3100 (enzalutamide), a breach of contract suit claims. The company expects to launch MDV3100 later this year.

You may also be interested in...



With New Data For A Drug In Dispute, Aragon Raises $50 Million

The San Diego biotech’s Series D round will support continued development of a drug that Medivation claims was included in the same license that covered the recently approved prostate cancer drug Xtandi.

More Competition In Prostate Cancer? Medivation’s Enzalutamide Now With FDA

Medivation and Astellas have submitted their castration-resistant prostate cancer drug enzalutamide to FDA and hope to gain priority review for the long-anticipated therapy.

Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial

A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel